Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus
Clinical and Molecular Hepatology
;
: 168-176, 2014.
Artigo
em Inglês
| WPRIM
| ID: wpr-119487
ABSTRACT
BACKGROUND/AIMS:
Adefovir dipivoxil (ADV) is a nucleotide analogue that is effective against lamivudine-resistant hepatitis B virus (HBV). The aim of this study was to determine the long-term clinical outcomes after ADV rescue therapy in decompensated patients infected with lamivudine-resistant HBV.METHODS:
In total, 128 patients with a decompensated state and lamivudine-resistant HBV were treated with ADV at a dosage of 10 mg/day for a median of 33 months in this multicenter cohort study.RESULTS:
Following ADV treatment, 86 (72.3%) of 119 patients experienced a decrease in Child-Pugh score of at least 2 points, and the overall end-stage liver disease score decreased from 16+/-5 to 14+/-10 (mean +/- SD, P or =2 points; P=0.001) and high mortality following ADV rescue therapy (P=0.012).CONCLUSIONS:
Three years of ADV treatment was effective and safe in decompensated patients with lamivudine-resistant HBV.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Antivirais
/
Índice de Gravidade de Doença
/
DNA Viral
/
Adenina
/
Razão de Chances
/
Vírus da Hepatite B
/
Taxa de Sobrevida
/
Estudos Retrospectivos
/
Estudos de Coortes
/
Lamivudina
Tipo de estudo:
Estudo de etiologia
/
Estudo de incidência
/
Estudo observacional
/
Fatores de risco
Limite:
Adulto
/
Idoso
/
Feminino
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Clinical and Molecular Hepatology
Ano de publicação:
2014
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS